Yubo International Biotech Limited (YBGJ)
USD 0.09
(-0.22%)
USD 0.09
(-0.22%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 2.91 Million USD | -38.24% |
| 2021 | 4.71 Million USD | 269.42% |
| 2020 | 1.27 Million USD | -23.43% |
| 2019 | 1.66 Million USD | 9.66% |
| 2018 | 1.52 Million USD | 10.54% |
| 2017 | 1.37 Million USD | 8.18% |
| 2016 | 1.27 Million USD | 11.29% |
| 2015 | 1.14 Million USD | 11.73% |
| 2014 | 1.02 Million USD | 11.07% |
| 2013 | 921 Thousand USD | 13.28% |
| 2012 | 813 Thousand USD | 11.52% |
| 2011 | 729 Thousand USD | 17.96% |
| 2010 | 618 Thousand USD | 17.27% |
| 2009 | 527 Thousand USD | 34.44% |
| 2008 | 392 Thousand USD | 23.27% |
| 2007 | 318 Thousand USD | 26.19% |
| 2006 | 252 Thousand USD | -25.44% |
| 2005 | 338 Thousand USD | -27.16% |
| 2004 | 464 Thousand USD | -42.36% |
| 2003 | 805 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 3.11 Million USD | 5.4% |
| 2023 Q1 | 2.95 Million USD | 1.32% |
| 2022 Q1 | 5.22 Million USD | 10.75% |
| 2022 Q3 | 4.37 Million USD | -17.44% |
| 2022 FY | 2.91 Million USD | -38.24% |
| 2022 Q2 | 5.3 Million USD | 1.46% |
| 2022 Q4 | 2.91 Million USD | -33.44% |
| 2021 Q4 | 4.71 Million USD | 14.11% |
| 2021 Q3 | 4.13 Million USD | 14.68% |
| 2021 FY | 4.71 Million USD | 269.42% |
| 2021 Q1 | 2.98 Million USD | 133.38% |
| 2021 Q2 | 3.6 Million USD | 20.96% |
| 2020 Q2 | - USD | 100.0% |
| 2020 Q3 | 1.48 Million USD | 0.0% |
| 2020 FY | 1.27 Million USD | -23.43% |
| 2020 Q4 | 1.27 Million USD | -13.93% |
| 2020 Q1 | -148 Thousand USD | -108.37% |
| 2019 Q2 | 1.66 Million USD | 0.0% |
| 2019 Q1 | 1.66 Million USD | 2.02% |
| 2019 Q4 | 1.76 Million USD | 1.96% |
| 2019 FY | 1.66 Million USD | 9.66% |
| 2019 Q3 | 1.73 Million USD | 3.96% |
| 2018 Q4 | 1.63 Million USD | 2.12% |
| 2018 Q3 | 1.6 Million USD | 0.0% |
| 2018 Q2 | - USD | -100.0% |
| 2018 Q1 | 1.52 Million USD | 1.06% |
| 2018 FY | 1.52 Million USD | 10.54% |
| 2017 Q1 | 1.37 Million USD | 0.44% |
| 2017 FY | 1.37 Million USD | 8.18% |
| 2017 Q3 | 1.46 Million USD | 0.0% |
| 2017 Q4 | 1.5 Million USD | 2.94% |
| 2017 Q2 | - USD | -100.0% |
| 2016 Q1 | 1.27 Million USD | 2.91% |
| 2016 FY | 1.27 Million USD | 11.29% |
| 2016 Q4 | 1.37 Million USD | 2.39% |
| 2016 Q3 | 1.33 Million USD | 0.0% |
| 2016 Q2 | - USD | -100.0% |
| 2015 Q3 | - USD | -100.0% |
| 2015 FY | 1.14 Million USD | 11.73% |
| 2015 Q1 | 1.14 Million USD | 2.97% |
| 2015 Q4 | 1.23 Million USD | 0.0% |
| 2015 Q2 | 1.14 Million USD | 0.0% |
| 2014 Q1 | 1.02 Million USD | 1.69% |
| 2014 Q3 | 1.07 Million USD | 5.18% |
| 2014 FY | 1.02 Million USD | 11.07% |
| 2014 Q2 | 1.02 Million USD | 0.0% |
| 2014 Q4 | 1.11 Million USD | 3.16% |
| 2013 Q1 | 921 Thousand USD | 3.6% |
| 2013 Q4 | 1 Million USD | 0.0% |
| 2013 FY | 921 Thousand USD | 13.28% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | -100.0% |
| 2012 Q1 | 813 Thousand USD | 2.65% |
| 2012 Q2 | 813 Thousand USD | 0.0% |
| 2012 Q3 | 869 Thousand USD | 6.89% |
| 2012 Q4 | 889 Thousand USD | 2.3% |
| 2012 FY | 813 Thousand USD | 11.52% |
| 2011 FY | 729 Thousand USD | 17.96% |
| 2011 Q2 | 729 Thousand USD | 0.0% |
| 2011 Q3 | 778 Thousand USD | 6.72% |
| 2011 Q4 | 792 Thousand USD | 1.8% |
| 2011 Q1 | 729 Thousand USD | 2.97% |
| 2010 Q3 | 689 Thousand USD | 11.49% |
| 2010 FY | 618 Thousand USD | 17.27% |
| 2010 Q4 | 708 Thousand USD | 2.76% |
| 2010 Q1 | 618 Thousand USD | 0.0% |
| 2010 Q2 | 618 Thousand USD | 0.0% |
| 2009 FY | 527 Thousand USD | 34.44% |
| 2009 Q1 | 527 Thousand USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 Q1 | 392 Thousand USD | 0.0% |
| 2008 FY | 392 Thousand USD | 23.27% |
| 2007 Q1 | 318 Thousand USD | 0.0% |
| 2007 FY | 318 Thousand USD | 26.19% |
| 2006 FY | 252 Thousand USD | -25.44% |
| 2006 Q1 | 252 Thousand USD | 0.0% |
| 2005 FY | 338 Thousand USD | -27.16% |
| 2005 Q1 | 338 Thousand USD | 0.0% |
| 2004 Q1 | 464 Thousand USD | 0.0% |
| 2004 FY | 464 Thousand USD | -42.36% |
| 2003 FY | 805 Thousand USD | 0.0% |
| 2003 Q1 | 805 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Medical Technologies Inc. | 2.34 Million USD | -24.005% |
| Ansell Limited | 1.32 Billion USD | 99.781% |
| Ansell Limited | 1.33 Billion USD | 99.781% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 126.33 Million USD | 97.694% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 943.17 Thousand USD | -208.949% |
| Psykey, Inc. | 2.47 Million USD | -17.781% |
| ConvaTec Group Plc | 2.01 Billion USD | 99.856% |
| ConvaTec Group Plc | 2.02 Billion USD | 99.856% |
| Encision Inc. | 1.98 Million USD | -46.874% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | 3.04 Million USD | 4.162% |
| Innovative MedTech Inc. | 6.13 Million USD | 52.502% |
| LifePoint, Inc. | 2.45 Million USD | -18.734% |
| Medite Cancer Diagnostics, Inc. | 10.18 Million USD | 71.379% |
| Paradigm Medical Industries, Inc. | 3.4 Million USD | 14.296% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 3.04 Million USD | 4.157% |
| Reflect Scientific, Inc. | 776.32 Thousand USD | -275.347% |
| SmileDirectClub, Inc. | 982.26 Million USD | 99.703% |
| Sector 10, Inc. | 9.84 Million USD | 70.403% |
| Shandong Weigao Group Medical Polymer Company Limited | 1.35 Billion USD | 99.785% |
| SheerVision, Inc. | 1.43 Million USD | -103.571% |
| United Health Products, Inc. | 1.99 Million USD | -45.779% |
| Vasamed, Inc. | 1 Million USD | -189.856% |
| Wearable Health Solutions, Inc. | 3.8 Million USD | 23.324% |